RILOMET-1: An international phase III multicenter, randomized, double-blind, placebo-controlled trial of rilotumumab plus epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in patients with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma Meeting Abstract
| Authors: | Cunningham, D.; Al-Batran, S. E.; Davidenko, I.; Ilson, D. H.; Murad, A. M.; Tebbutt, N. C.; Jiang, Y.; Lou, E.; Dubey, S. |
| Abstract Title: | RILOMET-1: An international phase III multicenter, randomized, double-blind, placebo-controlled trial of rilotumumab plus epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in patients with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma |
| Meeting Title: | 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 31 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2013 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2013-05-20 |
| Language: | English |
| ACCESSION: | WOS:000335419605437 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2013.31.15_suppl.TPS4153 |
| Notes: | Meeting Abstract: TPS4153 -- Source: Wos |
